Edwards Lifesciences Corporation (EW)
$
77.73
+1.07 (1.38%)
Key metrics
Financial statements
Free cash flow per share
0.4940
Market cap
44.7 Billion
Price to sales ratio
8.0723
Debt to equity
0.0700
Current ratio
4.1758
Income quality
0.1299
Average inventory
1.1 Billion
ROE
0.4904
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Edwards Lifesciences Corporation specializes in providing innovative products and technologies aimed at treating structural heart disease, as well as critical care and surgical monitoring solutions in various global markets including the United States, Europe, and Japan. The company recorded an operating income of $1,378,700,000.00 reflecting its earnings from core operations. It reported a substantial revenue of $5,439,500,000.00 showcasing its strong market presence in the industry. The company offers transcatheter heart valve replacement products, allowing for minimally invasive heart valve replacements, along with transcatheter valve repair and replacement products targeting mitral and tricuspid valve diseases. Additionally, the company provides the PASCAL and Cardioband transcatheter valve repair systems, which facilitate minimally-invasive therapies. In terms of surgical structural heart solutions, it offers solutions like the aortic surgical valve under the INSPIRIS name and KONECT RESILIA, a pre-assembled aortic tissue valved conduit designed for patients needing valve and root replacements alongside the ascending aorta. The HARPOON Beating Heart Mitral Valve Repair System is also available for patients suffering from degenerative mitral regurgitation. Furthermore, Edwards Lifesciences delivers critical care solutions including advanced hemodynamic monitoring systems that assess heart function and fluid status in surgical and intensive care settings, as well as the Acumen Hypotension Prediction Index software, which provides timely alerts to clinicians regarding dangerously low blood pressure. The company reported an income before tax of $1,548,100,000.00 showcasing its pre-tax profitability, and the operating income ratio stands at $0.25 indicating the company's operational profitability margin. In the financial market, the stock is reasonably priced at $77.73 appealing to a broad range of investors and reflecting the company’s robust standing. The stock has a high average trading volume of 4,823,308.00 indicating strong liquidity which can attract both new and seasoned investors. With a mid-range market capitalization of $45,596,418,000.00 the company continues to be a steady performer within its sector. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape while driving innovation and growth in the Healthcare sector.
Is Edwards Lifesciences Corporation (EW) a good investment?
Investing in Edwards Lifesciences Corporation (EW) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Edwards Lifesciences Corporation (EW)'s stock forecast?
Analysts predict Edwards Lifesciences Corporation stock to fluctuate between $58.93 (low) and $95.25 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Edwards Lifesciences Corporation's market capitalization?
As of 2025-05-30, Edwards Lifesciences Corporation's market cap is $45,596,418,000, based on 586,600,000 outstanding shares.
How does Edwards Lifesciences Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Edwards Lifesciences Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Edwards Lifesciences Corporation (EW) stock?
To buy Edwards Lifesciences Corporation (EW) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for EW. Place an order (Market, Limit, etc.).
What is the best time to invest in Edwards Lifesciences Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Edwards Lifesciences Corporation stock ever split?
Edwards Lifesciences Corporation's last stock split was 3:1 on 2020-06-01.
How did Edwards Lifesciences Corporation perform in the last earnings report?
Revenue: $5,439,500,000 | EPS: $6.98 | Growth: 202.16%.
Where can I find Edwards Lifesciences Corporation's investor relations reports?
Visit https://www.edwards.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Edwards Lifesciences Corporation?
You can explore historical data from here
What is the all-time high and low for Edwards Lifesciences Corporation stock?
All-time high: $131.73 (2021-12-30) | All-time low: $58.93 (2024-07-25).
What are the key trends affecting Edwards Lifesciences Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
businesswire.com
PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outco.
youtube.com
Bill Baruch, founder & president at Blue Line Capital, joins CNBC's 'Halftime Report' to detail his latest buy.
zacks.com
EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.
zacks.com
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.
seekingalpha.com
Edwards Lifesciences Corporation (NYSE:EW ) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Company Participants Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - Global Leader, TMTT Larry Wood - Global Group President, TAVR and Surgical Conference Call Participants Larry Biegelsen - Wells Fargo David Roman - Goldman Sachs Travis Steed - Bank of America Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Matt Taylor - Jefferies Joanne Wuensch - Citibank Pito Chickering - Deutsche Bank Chris Pasquale - Nephron Patrick Wood - Morgan Stanley Operator Greetings, and welcome to the Edwards Lifesciences First Quarter 2025 Results. [Operator Instructions] As a reminder, this conference is being recorded.
reuters.com
Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment.
zacks.com
Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
businesswire.com
CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves. For more than 65 years, Edwards has been the leader in heart valve innovations. To create a more durable heart valve, Edwards developed the RESILIA tissue technology more than two d.
zacks.com
EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds.
See all news
